Lumenis (NASDAQ:LUMEE)
Historical Stock Chart
From Oct 2019 to Oct 2024
Lumenis Announces New Global VP of Research and Development
YOKNEAM, Israel, Dec. 10 /PRNewswire-FirstCall/ -- Lumenis Ltd. has announced
today that Mr. Igor Gradov has joined Lumenis as the Global Vice President of
Research & Development.
"I am extremely pleased to welcome Igor to our team, in a position which I view
as a key strategic position in our company's future. Having a seasoned
executive such as Igor, with 25 years of successfully managing
multi-disciplinary and international engineering and scientific teams is a great
asset to us and to our customers, that expect us to continue to be leaders in
our markets," stated Mr. Avner Raz, President and Chief Executive Officer.
Mr. Gradov has spent his career dedicated to the design, development and product
introduction of light based medical products and technologies in the market
segments of Dermatology, Ophthalmology, Dentistry and General Surgery.
Mr. Gradov previously held positions as Director of Engineering at Coherent
Optical Division, Director of Research & Development at VISX Inc., Vice
President of Engineering for Palomar Medical Technologies, Vice President
Technology Development at Emory Vision Correction Group, and most recently as
COO of Luxano AB, Sweden.
About Lumenis
Lumenis develops, manufactures, and markets state-of-the-art proprietary laser
and intense pulsed light devices. Its systems are used in a variety of
aesthetic, ophthalmic, surgical and dental applications, including skin
treatments, hair removal, non-invasive treatment of vascular lesions and
pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign
prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary
cataracts, age-related macular degeneration, vision correction, neurosurgery,
dentistry and veterinary. For more information about the Company and its
products log on to http://www.lumenis.com/
The statements in this press release that are not historical facts are
forward-looking statements which are subject to risks and uncertainties. The
Company's actual results could differ materially from those anticipated in the
forward looking statements based on a variety of factors, including, among
others: uncertainties with respect to market acceptance of the Company's
products, obtaining regulatory approvals for new products or for the sale of
existing products in new markets and enforcement of intellectual property
rights; risks associated with competition and competitive pricing pressures,
economic conditions generally, the Company's international operations and the
Company's ability to integrate its operations with those of acquired businesses;
the outcome of the Securities and Exchange Commission investigation and several
securities class action lawsuits to which the Company is subject; uncertainties
relating to the Company's continuing liquidity; and other risks detailed from
time to time in the reports filed by Lumenis with the SEC, including its annual
report on Form 10-K and quarterly reports on Form 10-Q.
Contacts:
Kevin Morano
CFO
212-515-4187
DATASOURCE: Lumenis Ltd.
CONTACT: Kevin Morano, CFO of Lumenis Ltd., +1-212-515-4187
Web Site: http://www.lumenis.com/